Michael F Good

List of Publications by Year
in descending order

108 papers	4,767 citations	71102 41 h-index	110387 64 g-index
108 all docs	108 docs citations	108 times ranked	3563 citing authors

#	Article	IF	Citations
1	Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet, The, 2002, 360, 610-617.	13.7	376
2	Protection against Group A Streptococcus by Immunization with J8â€“Diphtheria Toxoid: Contribution of J8â€•and Diphtheria Toxoidâ€“Specific Antibodies to Protection. Journal of Infectious Diseases, 2003, 187, 1598-1608.	4.0	176
3	Polyacrylate Dendrimer Nanoparticles: A Selfâ€Adjuvanting Vaccine Delivery System. Angewandte Chemie - International Edition, 2010, 49, 5742-5745.	13.8	149
4	New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nature Medicine, 2000, 6, 455-459.	30.7	147
5	PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria. Cell Reports, 2013, 5, 1204-1213.	6.4	147
6	PATHWAYS AND STRATEGIES FOR DEVELOPING A MALARIA BLOOD-STAGE VACCINE. Annual Review of Immunology, 1998, 16, 57-87.	21.8	144
7	The Mechanism and Significance of Deletion of Parasite-specific CD4+T Cells in Malaria Infection. Journal of Experimental Medicine, 2002, 195, 881-892.	8.5	139
8	Status of research and development of vaccines for Streptococcus pyogenes. Vaccine, 2016, 34, 2953-2958.	3.8	113
9	Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. International Immunology, 1994, 6, 1235-1244.	4.0	106
10	Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Science Translational Medicine, 2019, 11, .	12.4	102
11	A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunology, Immunotherapy, 1997, 44, 10-20.	4.2	101
12	Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. Journal of Experimental Medicine, 2013, 210, 1635-1646.	8.5	94
13	â€˜Naturalâ€™ T cells responsive to malaria: evidence implicating immunological cross-reactivity in the maintenance of TCRÎ±Î²+ malaria-specific responses from non-exposed donors. International Immunology, 1992, 4, 985-994.	4.0	85
14	Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. Science Advances, 2020, 6, eaax2285.	10.3	85
15	Prolonged Th1â€like response generated by a Plasmodium yoeli â€specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunology, 1997, 19, 111-126.	1.5	83
16	Heterologous Immunity in the Absence of Variant-Specific Antibodies after Exposure to Subpatent Infection with Blood-Stage Malaria. Infection and Immunity, 2005, 73, 2478-2485.	2.2	78
17	Cross-species malaria immunity induced by chemically attenuated parasites. Journal of Clinical Investigation, 2013, 123, 3353-3362.	8.2	75
18	Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 168-173.	3.3	73

#	Article	IF	Citations
19	Intranasal Vaccination with a Lipopeptide Containing a Conformationally Constrained Conserved Minimal Peptide, a Universal T Cell Epitope, and a Selfâ€Adjuvanting Lipid Protects Mice from Group A Streptococcus Challenge and Reduces Throat Colonization. Journal of Infectious Diseases, 2006, 194, 325-330.	4.0	72
20	Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. Journal of Clinical Investigation, 2010, 120, 2967-2978.	8.2	70
21	Potential of Lipid Core Peptide Technology as a Novel Self-Adjuvanting Vaccine Delivery System for Multiple Different Synthetic Peptide Immunogens. Infection and Immunity, 2003, 71, 2373-2383.	2.2	68
22	A Lipid Core Peptide Construct Containing a Conserved Region Determinant of the Group A Streptococcal M Protein Elicits Heterologous Opsonic Antibodies. Infection and Immunity, 2002, 70, 2734-2738.	2.2	64
23	Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine, 1997, 15, 1805-1812.	3.8	59
24	Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunology, 1999, 21, 319-329.	1.5	59
25	Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE, 2018, 13, e0198658.	2.5	59
26	Polyacrylate-Based Delivery System for Self-adjuvanting Anticancer Peptide Vaccine. Journal of Medicinal Chemistry, 2015, 58, 888-896.	6.4	56
27	High frequency of malaria-specific T cells in non-exposed humans. European Journal of Immunology, 1992, 22, 689-696.	2.9	55
28	â€˜Original antigenic sinâ€™, T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion. Parasite Immunology, 1993, 15, 187-193.	1.5	54
29	Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine, 2002, 20, 2816-2825.	3.8	52
30	emmand C-Repeat Region Molecular Typing of Beta-Hemolytic Streptococci in a Tropical Country: Implications for Vaccine Development. Journal of Clinical Microbiology, 2009, 47, 2502-2509.	3.9	52
31	Toward the Development of an Antidisease, Transmissionâ€Blocking Intranasal Vaccine for Group A Streptococcus. Journal of Infectious Diseases, 2005, 192, 1450-1455.	4.0	51
32	Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11205-11210.	7.1	51
33	Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models. MBio, 2016, 7, .	4.1	51
34	The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2628-2633.	7.1	50
35	A Synthetic M Protein Peptide Synergizes with a CXC Chemokine Protease To Induce Vaccine-Mediated Protection against Virulent Streptococcal Pyoderma and Bacteremia. Journal of Immunology, 2015, 194, 5915-5925.	0.8	50
36	Inhibition of Plasmodium falciparum growth in vitro by CD4+and CD8+T cells from non-exposed donors. Parasite Immunology, 1994, 16, 579-586.	1.5	49

#	Article	IF	Citations
37	Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. Journal of Autoimmunity, 2003, 20, 211-217.	6.5	49
38	The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunological Reviews, 2004, 201, 254-267.	6.0	49
39	Intranasal Administration Is an Effective Mucosal Vaccine Delivery Route for Selfâ€Adjuvanting Lipid Core Peptides Targeting the Group A Streptococcal M Protein. Journal of Infectious Diseases, 2006, 194, 316-324.	4.0	48
40	Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nature Medicine, 1998, 4, 1193-1196.	30.7	47
41	Whole parasite blood stage malaria vaccines: A convergence of evidence. Hum Vaccin, 2010, 6, 114-123.	2.4	46
42	Mechanism of Protection Induced by Group A Streptococcus Vaccine Candidate J8-DT: Contribution of B and T-Cells Towards Protection. PLoS ONE, 2009, 4, e5147.	2.5	42
43	Long-Term Antibody Memory Induced by Synthetic Peptide Vaccination Is Protective against Streptococcus pyogenes Infection and Is Independent of Memory T Cell Help. Journal of Immunology, 2013, 190, 2692-2701.	0.8	41
44	Self-adjuvanting vaccine against group A streptococcus: Application of fibrillized peptide and immunostimulatory lipid as adjuvant. Bioorganic and Medicinal Chemistry, 2014, 22, 6401-6408.	3.0	41
45	Intranasal immunization with yeastâ€expressed 19â€ƒkD carboxylâ€terminal fragment ofPlasmodium yoeliimerozoite surface proteinâ€1 (yMSP119) induces protective immunity to blood stage malaria infection in mice. Parasite Immunology, 1998, 20, 413-420.	1.5	40
46	Immunization with a Tetraepitopic Lipid Core Peptide Vaccine Construct Induces Broadly Protective Immune Responses against Group A Streptococcus. Journal of Infectious Diseases, 2006, 193, 1666-1676.	4.0	38
47	Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity. Nanomedicine, 2014, 9, 2613-2624.	3.3	38
48	Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malaria Journal, 2015, 14, 143.	2.3	38
49	Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci. Journal of Immunology, 2016, 196, 3364-3374.	0.8	38
50	Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine, 2013, 31, 1950-1955.	3.8	37
51	M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Research in Microbiology, 2005, 156, 575-582.	2.1	35
52	Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci. Expert Review of Vaccines, 2015, 14, 1459-1470.	4.4	34
53	Natural amino acid polymorphisms of the circumsporozoite protein ofPlasmodium falciparum abrogate specific human CD4+ T cell responsiveness. European Journal of Immunology, 1994, 24, 1418-1425.	2.9	33
54	Rheumatic heart disease: A review of the current status of global research activity. Autoimmunity Reviews, 2021, 20, 102740.	5.8	32

#	Article	IF	Citations
55	Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection. Infection and Immunity, 2016, 84, 2274-2288.	2.2	31
56	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine, 2019, 37, 3485-3494.	3.8	31
57	Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naÃ¯ve volunteers: a pilot study. BMC Medicine, 2018, 16, 184.	5.5	29
58	Novel platform technology for modular mucosal vaccine that protects against streptococcus. Scientific Reports, 2016, 6, 39274.	3.3	26
59	Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma. PLoS Pathogens, 2016, 12, e1006122.	4.7	26
60	Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends in Immunology, 2005, 26, 295-297.	6.8	24
61	A semi-synthetic whole parasite vaccine designed to protect against blood stage malaria. Acta Biomaterialia, 2016, 44, 295-303.	8.3	24
62	The Impact of Established Immunoregulatory Networks on Vaccine Efficacy and the Development of Immunity to Malaria. Journal of Immunology, 2016, 197, 4518-4526.	0.8	23
63	Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial. Scientific Reports, 2017, 7, 13786.	3.3	23
64	Development of immunity to malaria may not be an entirely active process. Parasite Immunology, 1995, 17, 55-59.	1.5	22
65	Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine, 2007, 25, 3567-3573.	3.8	22
66	Strategies in the development of vaccines to prevent infections with group A streptococcus. Human Vaccines and Immunotherapeutics, 2013, 9, 2393-2397.	3.3	22
67	Linear and branched polyacrylates as a delivery platform for peptide-based vaccines. Therapeutic Delivery, 2016, 7, 601-609.	2.2	21
68	Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins. Molecular Immunology, 1997, 34, 433-440.	2.2	20
69	Antibodies to Cryptic Epitopes in Distant Homologues Underpin a Mechanism of Heterologous Immunity betweenPlasmodium vivaxPvDBP andPlasmodium falciparumVAR2CSA. MBio, 2019, 10, .	4.1	20
70	Examining cellular immune responses to inform development of a blood-stage malaria vaccine. Parasitology, 2016, 143, 208-223.	1.5	19
71	Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Human Vaccines and Immunotherapeutics, 2013, 9, 488-496.	3.3	18
72	Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes. Immunology and Cell Biology, 1990, 68, 317-324.	2.3	16

#	Article	IF	Citations
73	Vaccination Against Rheumatic Heart Disease: A Review of Current Research Strategies and Challenges. Current Infectious Disease Reports, 2012, 14, 381-390.	3.0	16
74	Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAFÂ®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes. MBio, 2021, 12, .	4.1	16
75	Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen. Journal of Immunology, 2017, 199, 2794-2802.	0.8	15
76	The importance of T cell homing and the spleen in reaching a balance between malaria immunity and immunopathology: The moulding of immunity by early exposure to crossâ€reactive organisms. Immunology and Cell Biology, 1992, 70, 405-410.	2.3	14
77	Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite. Infection and Immunity, 2016, 84, 2689-2696.	2.2	14
78	Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate. Human Vaccines and Immunotherapeutics, 2016, 12, 3089-3096.	3.3	14
79	Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy. Npj Vaccines, 2018, 3, 15.	6.0	14
80	Contribution of cryptic epitopes in designing a group A streptococcal vaccine. Human Vaccines and Immunotherapeutics, 2018, 14, 2034-2052.	3.3	14
81	Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines. Scientific Reports, 2021, 11, 127.	3.3	14
82	Pre-clinical evaluation of a whole-parasite vaccine to control human babesiosis. Cell Host and Microbe, 2021, 29, 894-903.e5.	11.0	14
83	Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice. Science Advances, 2019, 5, eaax3013.	10.3	13
84	Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites. Infection and Immunity, 2019, 87, .	2.2	13
85	Antibodies to neutralising epitopes synergistically block the interaction of the receptorâ€binding domain of SARSâ€CoVâ€2 to ACE 2. Clinical and Translational Immunology, 2021, 10, e1260.	3.8	13
86	M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP). Npj Vaccines, 2020, 5, 74.	6.0	12
87	Interpreting challenge data from early phase malaria blood stage vaccine trials. Expert Review of Vaccines, 2018, 17, 189-196.	4.4	11
88	Whole parasite vaccines for the asexual blood stages of Plasmodium. Immunological Reviews, 2020, 293, 270-282.	6.0	11
89	Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys. International Journal for Parasitology, 2016, 46, 581-591.	3.1	10
90	Synthesis, Characterization and Immunological Evaluation of Selfâ€Adjuvanting Groupâ€…A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties. ChemBioChem, 2017, 18, 545-553.	2.6	10

#	Article	IF	Citations
91	Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria. International Journal for Parasitology, 2002, 32, 575-580.	3.1	9
92	Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. International Journal of Peptide Research and Therapeutics, 2003, 10, 605-613.	0.1	9
93	Synthesis and Immunological Evaluation of M Protein Targeted Tetra-Valent and Tri-Valent Group A Streptococcal Vaccine Candidates Based on the Lipid-Core Peptide System. International Journal of Peptide Research and Therapeutics, 2006, 12, 317-326.	1.9	9
94	Streptococcus: An organism causing diseases beyond neglect. PLoS Neglected Tropical Diseases, 2020, 14, e0008095.	3.0	8
95	Malaria's journey through the lymph node. Nature Medicine, 2007, 13, 1023-1024.	30.7	7
96	Cryptic epitope for antibodies should not be forgotten in vaccine design. Expert Review of Vaccines, 2016, 15, 675-676.	4.4	7
97	Correlation between Bioluminescence and Bacterial Burden in Passively Protected Mice Challenged with a Recombinant Bioluminescent M49 Group A Streptococcus Strain. Vaccine Journal, 2010, 17, 127-133.	3.1	6
98	Cellular interactions of covR/S mutant group A Streptococci. Microbes and Infection, 2018, 20, 531-535.	1.9	5
99	Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation. Clinical and Translational Immunology, 2018, 7, e1015.	3.8	5
100	In Search of the Holy Grail: A Specific Diagnostic Test for Rheumatic Fever. Frontiers in Cardiovascular Medicine, 2021, 8, 674805.	2.4	5
101	Combinatorial liposomal peptide vaccine induces IgA and confers protection against influenza virus and bacterial superâ€infection. Clinical and Translational Immunology, 2021, 10, e1337.	3.8	5
102	A Superficial Skin Scarification Method in Mice to Mimic Streptococcus pyogenes Skin Infection in Humans. Methods in Molecular Biology, 2020, 2136, 287-301.	0.9	5
103	Tying the conductor's arms. Nature, 1999, 400, 25-26.	27.8	4
104	Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Indian Journal of Medical Research, 2004, 119 Suppl, 88-94.	1.0	4
105	Peptide-Protein Conjugation and Characterization to Develop Vaccines for Group A Streptococcus. Methods in Molecular Biology, 2021, 2355, 17-33.	0.9	2
106	Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. International Journal of Peptide Research and Therapeutics, 2003, 10, 605-613.	1.9	1
107	SENSITIVITY AND RESISTANCE OF HUMAN MELANOMA CELLS TO ULTRAVIOLET RADIATION. The Australian Journal of Experimental Biology and Medical Science, 1981, 59, 515-520.	0.7	0
108	Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens. PLoS ONE, 2022, 17, e0264961.	2.5	0